Achieve Life Sciences (ACHV) Income from Continuing Operations (2010 - 2018)
Achieve Life Sciences' (ACHV) quarterly Income from Continuing Operations came in at 3637000.0 in Q4 2018, up 2.75% YoY from 3539521.21 in Q4 2017, and down 12.25% on a QoQ basis from 3240000.0 in Q3 2018.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Income from Continuing Operations (2010 - 2018) Analysis & Trends
Achieve Life Sciences (ACHV) has 7 years of Income from Continuing Operations data on file, last reported at 3637000.0 in Q4 2018.
- Quarterly Income from Continuing Operations rose 2.75% year-over-year to 3637000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 12687000.0 (up 6.95% YoY) and the FY2019 annual result came in at 16395000.0, down 29.23% from the prior year.
- Income from Continuing Operations fell to 3637000.0 in Q4 2018, from 3240000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 166000.0 in Q2 2017 to a low of 9400000.0 in Q3 2017.
- A 4-year average of 2597727.27 and a median of 2788000.0 in 2018 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2017 — Income from Continuing Operations sank 2220.99% — and 2018, when it soared 65.53%.
- Tracing ACHV's Income from Continuing Operations over 4 years: stood at 1235000.0 in 2015, then surged by 50.36% to 613000.0 in 2016, then plunged by 510.11% to 3740000.0 in 2017, then rose by 2.75% to 3637000.0 in 2018.
- The last three Income from Continuing Operations figures came in at 3637000.0 (Q4 2018), 3240000.0 (Q3 2018), and 2788000.0 (Q2 2018), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -3.64 Mn |
| Sep 30, 2018 | -3.24 Mn |
| Jun 30, 2018 | -2.79 Mn |
| Mar 31, 2018 | -3.02 Mn |
| Dec 31, 2017 | -3.74 Mn |
| Sep 30, 2017 | -9.40 Mn |
| Jun 30, 2017 | -166,000.00 |
| Mar 31, 2017 | -329,000.00 |
| Dec 31, 2016 | -613,000.00 |
| Sep 30, 2016 | -405,000.00 |
| Dec 31, 2015 | -1.24 Mn |
| Dec 31, 2012 | -38.09 Mn |
| Sep 30, 2012 | 5.92 Mn |
| Jun 30, 2012 | 4.22 Mn |
| Mar 31, 2012 | -6.86 Mn |
| Dec 31, 2011 | -19.78 Mn |
| Sep 30, 2011 | -4.47 Mn |
| Jun 30, 2011 | 6.53 Mn |
| Mar 31, 2011 | -3.05 Mn |
| Dec 31, 2010 | -2.80 Mn |